DSGN

Design Therapeutics Inc

Aug 29 • 04:00PM ET

5.53

Dollar change -0.11
Percentage change -1.95	%

Healthcare • Biotechnology • USA • NASD

Peers: PFE REGN VRTX MRNA BNTX CRSP EDIT NTLA SGMO BEAM

| Held by: IWM VTI IWN VXF IBB SCHA VTWO FESM IWC ONEQ

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.12	Insider Own	45.61%	Shs Outstand	56.95M	Perf Week	5.13%
Market Cap	314.92M	Forward P/E	-	EPS next Y	-1.22	Insider Trans	-2.12%	Shs Float	30.97M	Perf Month	42.89%
Enterprise Value	100.59M	PEG	-	EPS next Q	-0.34	Inst Own	45.84%	Short Float	11.33%	Perf Quarter	48.26%
Income	-63.49M	P/S	-	EPS this Y	-51.89%	Inst Trans	-2.01%	Short Ratio	30.93	Perf Half Y	13.79%
Sales	0.00M	P/B	1.48	EPS next Y	8.98%	ROA	-25.78%	Short Interest	3.51M	Perf YTD	-10.37%
Book/sh	3.74	P/C	1.46	EPS next 5Y	-17.11%	ROE	-26.77%	52W High	7.77 -28.83%	Perf Year	12.40%
Cash/sh	3.80	P/FCF	-	EPS past 3/5Y	-10.99% -88.52%	ROIC	-29.65%	52W Low	2.60 112.69%	Perf 3Y	-73.52%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.77% 8.35%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-24.60%	Oper. Margin	-	ATR (14)	0.38	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	25.13	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	62.91	Recom	2.33
Dividend Gr. 3/5Y	- -	Current Ratio	25.13	EPS Q/Q	-60.96%	SMA20	11.53%	Beta	1.65	Target Price	7.33
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	27.88%	Rel Volume	1.98	Prev Close	5.64
Employees	54	LT Debt/Eq	0.01	Earnings	Aug 07 AMC	SMA200	19.69%	Avg Volume	113.42K	Price	5.53
IPO	Mar 26, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-3.03% -	Trades		Volume	224,142	Change	-1.95%

Date	Action	Analyst	Rating Change	Price Target Change
May-07-24	Upgrade	Piper Sandler	Neutral → Overweight	$6 → $12
Nov-14-23	Downgrade	Piper Sandler	Overweight → Neutral	$42 → $6
Aug-15-23	Downgrade	Wedbush	Outperform → Neutral	$19 → $6
Aug-15-23	Downgrade	SVB Securities	Outperform → Market Perform	$6
Aug-15-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$23 → $7
May-04-23	Upgrade	Goldman	Sell → Neutral	$6
Jun-10-22	Initiated	Wedbush	Outperform	$21
May-02-22	Initiated	RBC Capital Mkts	Outperform	$30
Jan-19-22	Initiated	Goldman	Sell	$10
Apr-20-21	Initiated	SVB Leerink	Outperform	$36
Apr-20-21	Initiated	Piper Sandler	Overweight	$42
Apr-20-21	Initiated	Goldman	Neutral	$28

Show Previous Ratings

Aug-27-25 08:00AM	Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference (GlobeNewswire)
Aug-07-25 04:01PM	Design Therapeutics Highlights Progress Across Lead GeneTAC Programs and Reports Second Quarter 2025 Financial Results (GlobeNewswire) -8.74% +7.81%
Jun-04-25 07:00AM	Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2 (GlobeNewswire)
May-28-25 08:00AM	Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference (GlobeNewswire)
May-13-25 08:00AM	Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference (GlobeNewswire)
04:01PM	Loading…
May-07-25 04:01PM	Design Therapeutics Highlights Momentum Across Lead GeneTAC Programs and Reports First Quarter 2025 Financial Results (GlobeNewswire) -8.26% +5.71%
May-02-25 07:58AM	Design Therapeutics reports positive outcomes from trial of DT-168 eye drops (Clinical Trials Arena)
May-01-25 08:00AM	Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy (GlobeNewswire)
Apr-21-25 04:01PM	Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025 (GlobeNewswire) +10.31%
Apr-17-25 08:00AM	Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer (GlobeNewswire)
07:00AM	Bright Peak Therapeutics Appoints John Schmid to its Board of Directors (GlobeNewswire)
Mar-12-25 12:00PM	Design Therapeutics (DSGN) Upgraded to Buy: Here's Why (Zacks) -6.94%
Mar-10-25 07:07AM	Design Therapeutics Highlights Progress Across Lead GeneTAC Programs and Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-03-25 08:00AM	Design Therapeutics to Participate in Leerink's Global Healthcare Conference (GlobeNewswire) -7.00%
Nov-13-24 08:00AM	Design Therapeutics to Participate in Multiple Upcoming Investor Conferences (GlobeNewswire) +8.54%
04:01PM	Loading…
Nov-07-24 04:01PM	Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio (GlobeNewswire)
Sep-10-24 08:00AM	Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference (GlobeNewswire) +15.69%
Aug-21-24 09:55AM	Wall Street Analysts Think Design Therapeutics (DSGN) Could Surge 39.72%: Read This Before Placing a Bet (Zacks)
Aug-05-24 08:00AM	Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC Portfolio (GlobeNewswire)
May-22-24 08:50PM	The 100%+ Club: Piper Sandler's 3 Top Picks for Triple-Digit Gains (InvestorPlace)
May-10-24 03:36PM	Design Therapeutics Inc (DSGN) Q1 2024 Earnings: A Detailed Financial and Strategic Review (GuruFocus.com)
May-08-24 11:55PM	DSGN Stock Earnings: Design Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones (GlobeNewswire)
May-07-24 07:12AM	--Piper Sandler Upgrades Design Therapeutics to Overweight From Neutral (MT Newswires) +28.49%
06:30AM	Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
Mar-20-24 10:31AM	Design Therapeutics, Inc. (NASDAQ:DSGN) Q4 2023 Earnings Call Transcript (Insider Monkey) +11.97%
06:58AM	Q4 2023 Design Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-19-24 08:53PM	DSGN Stock Earnings: Design Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
05:33PM	Design Therapeutics Inc (DSGN) Reports Full Year 2023 Financial Results and Pipeline Progress (GuruFocus.com)
04:01PM	Design Therapeutics Outlines Progress Across GeneTAC Platform and Announces Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
06:30AM	Loading…
Mar-12-24 06:30AM	Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update (GlobeNewswire)
Dec-18-23 12:00PM	Design Therapeutics, Inc. (DSGN) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-14-23 07:28PM	Design Therapeutics Inc (DSGN) Reports Q3 2023 Financials, Plans Strategic Update (GuruFocus.com) +11.71%
Nov-13-23 04:05PM	Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024 (GlobeNewswire)
Aug-15-23 03:02PM	Why Shares of Design Therapeutics Are Plummeting on Tuesday (Motley Fool) -70.46%
09:59AM	Redfin upgraded, CSSE downgraded: Wall Street's top analyst calls (The Fly)
02:34AM	4 big analyst cuts: Urban Outfitters has 'limited' EPS upside, per Citi (Investing.com)
Aug-14-23 04:05PM	Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
04:01PM	Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia (GlobeNewswire)
Jun-18-23 08:03AM	Pleasing Signs As A Number Of Insiders Buy Design Therapeutics Stock \ (Simply Wall St.)
May-31-23 06:30AM	Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference (GlobeNewswire) -6.01%
May-09-23 04:05PM	Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results (GlobeNewswire) -11.66%
May-08-23 06:05AM	We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely (Simply Wall St.)
Apr-24-23 06:30AM	Design Therapeutics to Present Preclinical Data on its GeneTAC Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023 (GlobeNewswire)
Apr-11-23 09:55AM	Why Design Therapeutics (DSGN) Stock Is Going Nowhere But Down (InvestorPlace)
Apr-04-23 02:47PM	Down More Than 60%: Analysts Say Buy These 3 Beaten-Down Stocks Before They Rebound (TipRanks) -7.32%
Mar-14-23 04:05PM	Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Mar-09-23 06:33AM	Daily Vickers Top Insider Picks for 03/09/2023 (Argus Research)
Feb-08-23 06:30AM	Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference (GlobeNewswire) -8.79%
Dec-21-22 06:46AM	Daily Vickers Top Buyers & Sellers for 12/21/2022 (Argus Research) +5.33%
Dec-14-22 05:15AM	Independent Director Rodney Lappe Just Bought 15% More Shares In Design Therapeutics, Inc. (NASDAQ:DSGN) (Simply Wall St.)
Dec-07-22 04:01PM	Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress (GlobeNewswire) -6.00% -33.33%
Nov-28-22 10:37AM	Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth (Simply Wall St.)
Nov-03-22 04:05PM	Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-17-22 04:05PM	Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022 (GlobeNewswire)
Sep-22-22 06:30AM	Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit (GlobeNewswire)
Aug-08-22 04:05PM	Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-03-22 06:30AM	Design Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference (GlobeNewswire) +6.33%
Jun-21-22 09:57AM	Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth (Simply Wall St.) +6.24%
Jun-01-22 06:30AM	Design Therapeutics to Present at the 2022 Jefferies Healthcare Conference (GlobeNewswire)
May-09-22 04:05PM	Design Therapeutics Highlights Clinical and Research Progress and Reports First Quarter 2022 Financial Results (GlobeNewswire)
Mar-30-22 06:30AM	Design Therapeutics Completes Dosing in First Patient Cohort of Phase 1 Trial of DT-216 GeneTAC Molecule for the Treatment of Friedreich Ataxia (GlobeNewswire)
Mar-23-22 02:53PM	Design Therapeutics, Inc. (NASDAQ:DSGN) insiders placed bullish bets worth US$1.2m in the last 12 months (Simply Wall St.)
Mar-10-22 04:02PM	Design Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Mar-09-22 06:30AM	Design Therapeutics Announces Preclinical Data Highlighting Novel GeneTAC Therapy for the Treatment of Fuchs Endothelial Corneal Dystrophy to be Presented at ARVO 2022 (GlobeNewswire) +9.41%
Feb-28-22 04:05PM	Design Therapeutics Announces FDA Clearance of Investigational New Drug Application for First GeneTAC Molecule for Friedreich Ataxia (GlobeNewswire)
Feb-10-22 06:30AM	Design Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference (GlobeNewswire) +7.02%
Feb-01-22 04:05PM	Design Therapeutics Appoints Drug Development Expert, Jae Kim, M.D., as Chief Medical Officer (GlobeNewswire)
Jan-19-22 12:51PM	Design Therapeutics Shares Fall As Goldman Sachs Initiates With Sell Rating (Benzinga) -5.86%
Dec-23-21 05:00AM	Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.) +5.09%
Nov-09-21 04:05PM	Design Therapeutics Reports Pipeline Progress and Third Quarter 2021 Results (GlobeNewswire)
Sep-24-21 07:55AM	Design Therapeutics, Inc. (NASDAQ:DSGN) insiders placed bullish bets worth US$1.2m in the last 12 months (Simply Wall St.)
Sep-08-21 06:30AM	Design Therapeutics Announces Positive Preclinical Data Highlighting Disease-Modifying Potential of its Novel DM1 GeneTACs as a Treatment for Myotonic Dystrophy Type-1 (GlobeNewswire)
Sep-03-21 07:33AM	4 Stocks Insiders Are Buying (Benzinga)
Aug-09-21 04:05PM	Design Therapeutics Reports GeneTAC Portfolio Progress and Second Quarter 2021 Results (GlobeNewswire) +6.19%
Jun-26-21 04:30AM	We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely (Simply Wall St.)
Jun-07-21 04:10PM	Design Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference (GlobeNewswire)
04:05PM	Design Therapeutics Expands Board of Directors with Key Appointments (GlobeNewswire)
May-10-21 04:05PM	Design Therapeutics Announces Business Highlights and Reports First Quarter 2021 Financial Results (GlobeNewswire) -6.82%
Mar-30-21 04:05PM	Design Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire) -13.20%
Mar-25-21 11:56PM	Design Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. It is created to design, develop and commercialize a novel class of small molecule therapeutic candidates (GeneTACs) designed to directly address the underlying basis of genetic disease. The company was founded by Pratik Shah and Aseem Z. Ansari on December 18, 2017 and is headquartered in Carlsbad, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
William Arsani	Director	Aug 13 '25	Sale	5.25	562,627	2,953,792	1,000,000	Aug 14 04:15 PM
Logos Opportunities Fund II LP	Director	Aug 13 '25	Proposed Sale	4.98	217,627	1,083,783		Aug 13 08:05 PM
Logos Global Master Fund LP	Director	Aug 13 '25	Proposed Sale	4.98	345,000	1,718,100		Aug 13 08:04 PM
Prasad Deepa	Director	Dec 18 '24	Sale	6.27	3,806	23,864	20,000	Dec 19 06:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DSGN

Design Therapeutics Inc

Upgrade your FINVIZ experience